Alerta

神経変性疾患に関連するバイオマーカーを検出するためのデバイスおよび方法

Resumen de: MX2024013690A

The present disclosure provides devices for the detection and/or quantification of neurotoxic amyloid-type protein aggregates, comprising a doxycycline derivative immobilized on an appropriate surface, as well as electrochemical and immunochemical methods associated to the use of such devices.

生物流体バイオマーカーとしてのｂ－ｉｓｏｘ沈殿物または捕捉タンパク質を検出する方法

Resumen de: CN119866443A

Described herein are methods for detecting conformational diseases, aging, and proteinopathies by measuring the presence of b-isox precipitates and the level of b-isox capture proteins in biological fluids of healthy individuals and patients. The studies have identified additional biomarkers that make it possible to detect biomarkers by adding or not adding isoxazole to the obtained biological fluid sample, thereby making it possible to detect, diagnose or treat human diseases in a human subject. Diagnosis of disease using b-isox and/or biomarkers becomes possible.

- PHOSPHO-TAU ANTIBODIES AND METHODS OF USE

Resumen de: US2024360206A1

Provided herein are compositions and methods relating to improved assays for establishing Alzheimer's disease. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays.

BIOMARKERS FOR DIAGNOSING ALZHEIMER'S DISEASE AND RELATED DEMENTIAS

Resumen de: US2025224408A1

Provided herein are methods, compositions, and systems for diagnosing, assessing the likelihood of Alzheimer's disease, and assessing the rate of progression of Alzheimer's disease comprising assaying biofluid samples and identifying from the biofluid samples the presence/abundance of one or more biomarkers. Also provided herein are methods of assessing the likelihood of dementia progression or the rate of dementia progression comprising assaying biofluid samples and identifying from the biofluid samples the presence/abundance of one or more biomarkers.

MESENCHYMAL STROMAL CELL-DERIVED EXTRACELLULAR VESICLE-EXOSOMES

Resumen de: US2025222034A1

A method of generating MSC-derived exosome populations may include collecting MSC containing material from living tissue, separating desired mononuclear cells from granulocytes, culturing to multiply the cells, separation of desired cells for further multiplication by washing non-adherent cells and culturing adherent cells, repeating as necessary to obtain a suitably pure population of MSCs, culturing the MSCs in culture media containing negative/healing active cytokines interleukin-4 (IL-4) and interleukin-10 (IL-10) and multifunctional cytokine TGF-ß, and isolating the MSC-derived exosome populations. Diverse MSC-derived exosome populations may be generated by altering the cytokine composition of the culture media. The MSC-derived exosome populations may be screened for effectiveness in treatment of Long Covid using in vitro, in vivo, and pre-clinical testing utilizing model organisms. The exosomes may be administered nasally. Successful MSC-derived exosome populations may be further subjected to patient trials to establish efficacy in treatment of Long Covid via nasal administration of the MSC-derived exosome populations to human subjects. Similar methodologies may be employed to establish efficacy of the MSC-derived exosome populations for treatment of other diseases and conditions related to the central nervous system, spinal cord injury, or neurological diseases, such as Alzheimer disease.

AGENTS, USES AND METHODS FOR THE TREATMENT OF SYNUCLEINOPATHY

Resumen de: EP4582144A2

The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.

- DNA DNA APTAMERS SPECIFICALLY BINDING TO -SECRETASE PROTEIN AND USE THEREOF

Nº publicación: KR20250105736A 09/07/2025

Solicitante:

NAT UNIV CHUNGBUK IND ACAD COOP FOUND [KR]
\uCDA9\uBD81\uB300\uD559\uAD50 \uC0B0\uD559\uD611\uB825\uB2E8

Resumen de: KR20250105736A

본 발명은 β-세크레타제(β-secretase) 단백질에 특이적으로 결합하고 특정 폴리뉴클레오티드 서열로 구성되는 DNA 앱타머 및 상기 DNA 앱타머의 용도에 관한 것이다. 구체적으로, 본 발명에 따른 DNA 앱타머는 β-세크레타제 단백질에 특이적으로 강하게 결합함으로써, 상기 DNA 앱타머는 β-세크레타제 단백질의 검출이나, β-세크레타제 단백질의 발현 수준이 유의적으로 높아진 것으로 알려진 퇴행성뇌질환의 진단에 유용하게 사용될 수 있다.